Bluebird Bio Inc (BLUE) 157.18 $BLUE The Zacks Analyst

New Post Public Reply Private Reply Replies (0) Message Board

Jul 29, 2015 at 12:22 PM

Bluebird Bio Inc (BLUE) 157.18 $BLUE

The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 157.18 (-3.14), BIIB: 311.84 (-8.09), LGND: 103.20 (-2.64), REGN: 541.87 (-10.58), EXEL: 5.73 (+0.32)

Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 157.18 (-3.14), BIIB: 311.84 (-8.09), LGND: 103.20 (-2.64), AMGN: 171.86 (-0.88), REGN: 541.87 (-10.58), EXEL: 5.73 (+0.32), CELG: 133.93 (-1.49)

Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 157.18 (-3.14), BIIB: 311.84 (-8.09), NBIX: 50.03 (-1.89), ISIS: 53.13 (-1.27), SRPT: 31.80 (-0.23), RCPT: 227.79 (+0.63)

What's in bluebird bio's Pipeline That Has Investors So Excited?
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jul 19, 9:02AM CDT
Clinical-stage biotechnology company bluebird bio has been a stellar investment for early investors, with the stock up more than 500% since coming public in 2013. However, since bluebird has yet to bring a product to market, investors have been...
BLUE: 157.18 (-3.14)

Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.24 (unch), BLUE: 157.18 (-3.14), AMBA: 116.50 (-2.76), NFLX: 107.31 (+0.41), EYES: 13.90 (-0.20), AMZN: 527.32 (+1.29), ZIOP: 12.45 (-0.19), LNKD: 227.95 (-0.55), FB: 95.47 (+0.18), RCPT: 227.79 (+0.63), LBIO: 8.57 (-0.24), INTC: 29.02 (+0.06), ONTY: 3.50 (-0.01), CELG: 133.93 (-1.49)

Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.24 (unch), BLUE: 157.18 (-3.14), AMBA: 116.50 (-2.76), NFLX: 107.31 (+0.41), EYES: 13.90 (-0.20), AMZN: 527.32 (+1.29), ZIOP: 12.45 (-0.19), LNKD: 227.95 (-0.55), FB: 95.47 (+0.18), RCPT: 227.79 (+0.63), LBIO: 8.57 (-0.24), INTC: 29.02 (+0.06), ONTY: 3.50 (-0.01), CELG: 133.93 (-1.49)

An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.24 (unch), BLUE: 157.18 (-3.14), AMBA: 116.50 (-2.76), NFLX: 107.31 (+0.41), EYES: 13.90 (-0.20), AMZN: 527.32 (+1.29), ZIOP: 12.45 (-0.19), LNKD: 227.95 (-0.55), FB: 95.47 (+0.18), RCPT: 227.79 (+0.63), LBIO: 8.57 (-0.24), INTC: 29.02 (+0.06), ONTY: 3.50 (-0.01), CELG: 133.93 (-1.49)

Strong Finish Is Key for Market
at The Street - Mon Jul 13, 3:18PM CDT
But there's still the problem of limited upside momentum.
BLUE: 157.18 (-3.14), NFLX: 107.31 (+0.41), AMZN: 527.32 (+1.29), TDOC: 31.31 (+0.48), GUID: 9.09 (-0.27), CBM: 47.24 (+0.58), FB: 95.47 (+0.18), LBIO: 8.57 (-0.24), GOOGL: 655.93 (-3.73), MBLY: 59.15 (+0.36), AAPL: 122.67 (-0.71)

Market Action Is Good but the Chase Is Off
at The Street - Mon Jul 13, 11:53AM CDT
There should be a solid close, but it's dead in the meantime.
BLUE: 157.18 (-3.14), NFLX: 107.31 (+0.41), AMZN: 527.32 (+1.29), TDOC: 31.31 (+0.48), GUID: 9.09 (-0.27), CBM: 47.24 (+0.58), FB: 95.47 (+0.18), LBIO: 8.57 (-0.24), GOOGL: 655.93 (-3.73), MBLY: 59.15 (+0.36), AAPL: 122.67 (-0.71)

Stock-Picking Action Looks Good for Bulls
at The Street - Mon Jul 13, 9:17AM CDT
Players are happy to set Greece aside, at least temporarily.
BLUE: 157.18 (-3.14), NFLX: 107.31 (+0.41), AMZN: 527.32 (+1.29), TDOC: 31.31 (+0.48), GUID: 9.09 (-0.27), CBM: 47.24 (+0.58), FB: 95.47 (+0.18), LBIO: 8.57 (-0.24), GOOGL: 655.93 (-3.73), MBLY: 59.15 (+0.36), AAPL: 122.67 (-0.71)

Why Shares in Bluebird Bio Slumped By More Than 10% in June
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 08, 8:41AM CDT
A narrowing of its collaboration with biotech Goliath Celgene Corp led shares of bluebird bio to tumble 13.3% in June (via data from Capital IQ ). Casting aside CAR-T Bluebird bio and Celgene had previously been collaborating on the...
BLUE: 157.18 (-3.14), CELG: 133.93 (-1.49)

For The Record
at Investor's Business Daily - Mon Jul 06, 5:44PM CDT
For The Record: The ticker symbol of Bluebird Bio (BLUE) is BLUE. The symbol was wrongly identified in an ETFs story that ran July 2 on page A7.
BLUE: 157.18 (-3.14)

Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT

BLUE: 157.18 (-3.14), DRNA: 12.61 (-0.13), ALNY: 128.18 (-1.58), TKMR: 10.30 (+0.03), JUNO: 48.09 (-0.53), CELG: 133.93 (-1.49)

Critical Alerts For Seadrill, Health Net Inc., American Airlines, Horizon Pharma and bluebird bio Inc. Released By InvestorsObserver
PR Newswire - Mon Jul 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, HNT, AAL, HZNP and BLUE.
BLUE: 157.18 (-3.14), HZNP: 36.90 (-1.42), AAL: 41.05 (-0.12), SDRL: 9.58 (+0.60), HNT: 66.16 (+0.12)

Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
DoctoRx - at Seeking Alpha - Fri Jul 03, 10:12AM CDT

AGTC: 17.96 (-0.22), BLUE: 157.18 (-3.14), BIIB: 311.84 (-8.09), GILD: 116.83 (+3.76), AZN: 32.84 (+0.03), AMGN: 171.85 (-0.89), JUNO: 48.09 (-0.53), SRNE: 19.76 (-0.65), XLRN: 28.59 (-0.30), CELG: 133.93 (-1.49)

Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 157.18 (-3.14), KITE: 70.00 (-1.91), ADMS: 25.70 (-0.84), ACHN: 8.40 (-0.01)

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
at The Street - Thu Jul 02, 11:54AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 157.18 (-3.14), GILD: 116.83 (+3.76), MNKD: 4.46 (-0.36), PBYI: 83.66 (-3.56), KERX: 7.90 (-0.19), CELG: 133.93 (-1.49)

Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 157.18 (-3.14), KITE: 70.00 (-1.91), CLLS: 35.64 (-0.74), JUNO: 48.09 (-0.53), CYAD: 57.09 (+0.25), CELG: 133.93 (-1.49)

Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 8.24 (unch), NFLX: 107.31 (+0.41), BLUE: 157.18 (-3.14), AMZN: 527.32 (+1.29), TSLA: 266.61 (+1.79), KITE: 70.00 (-1.91), LBIO: 8.57 (-0.24), JUNO: 48.09 (-0.53), EGRX: 92.75 (-0.09)

A Good Cleanout Is Refreshing
at The Street - Tue Jun 30, 12:57PM CDT
And so is a shift in emotions.
SGYP: 8.24 (unch), NFLX: 107.31 (+0.41), BLUE: 157.18 (-3.14), AMZN: 527.32 (+1.29), TSLA: 266.61 (+1.79), KITE: 70.00 (-1.91), LBIO: 8.57 (-0.24), JUNO: 48.09 (-0.53), EGRX: 92.75 (-0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Starr Conspiracy Unveils AI Tool for B2B Tech Firms

AI-Driven Insight in Minutes: A Game Changer for B2B Hold onto your hats, because The Starr Conspiracy just lit a fire in the B2B tech world with its latest offering—Battle Card Builder. This free tool cranks out competitive intelligence in no time, literally about four minutes. Geared specifically for B2B tech marketing and sales teams, it combines decades of know-how...

BeyondCPG Accelerator Launches Seventh Growth Program

Fresh Faces in Conscious Consumerism There's nothing quite like an early morning jolt of caffeine mixed with the buzz of innovation in the air. BeyondCPG, a heavyweight in the conscious products arena, has cracked open the doors to its seventh round of powerhouse brand-boosting with the launch of its new Accelerator Track 7. They're mixing heart with hustle to give...

Spotlight on AI-Powered Smart Homes for 2027

Gearing Up for the Connected Home Revolution Ah, the thrill of peering into the future of smart homes! That's what's cookin' as Parks Associates gears up for its annual CONNECTIONS™ Conference slated for May 4-6, 2027. This isn't just another routine pow-wow. Nope, this get-together is about seeing who's leading the pack in transforming our everyday spaces into...

Sequel Advisors Rebrand: Founder-Centric M&A Focus

What's in a Name? A Shift to Reflect Reality When a company decides it's time to shake things up with a rebrand, they better have a good reason. Enter what's now called Sequel Advisors—shedding the old label, Transact Capital, to let founders know exactly what they’re dealing with upfront. This isn't just some slick, new logo on a letterhead. It's about aligning their...

New Podcast by Paralyzed Veterans of America Offers Unique Insights

Empowering Veterans Through Storytelling Some stories don't just rattle around in your headphones—they stick with you. The 'Voices of PVA' podcast, launched by Paralyzed Veterans of America, aims to do exactly that. It's not just a podcast; it's a platform where voices of veterans and people with spinal cord injuries like MS and ALS aren't just heard, they're amplified....

Alex Jones Returns to Austin: New Studio, New Plans

Back in the Saddle: Austin's Controversy Stirs Again It looks like we're seeing a new chapter in a saga that just refuses to end. Alex Jones, the infamous firebrand who's plastered conspiracy theories across the airwaves for two decades, is returning to ground zero in Austin—the old InfoWars studio. After wading through bankruptcy muck and courtroom clashes, Jones is...

Amy Wilson Joins ITSA Board: A New Era for UBI?

An Unexpected Turn in the UBI Movement In a world where tech and economic security must dance together, minding the steps is crucial. And this time, Amy Wilson's got her dancing shoes on. On September 24, 2026, the Income To Support All (ITSA) Foundation made some waves by adding Wilson to its board of directors, a move showing they're more serious than ever about...

Lincoln Educational Services Faces Securities Fraud Suit

A Storm Brews Over Lincoln Educational Services You know, there's nothing quite like the stink of a good mess in the markets, and Lincoln Educational Services Corporation has found itself knee-deep in one. The buzz is all about some securities fraud allegations that could rope in a bunch of investors who got the short end of the stick. It’s lawsuits like these that make...

Unicycive's Legal Turmoil: Opportunity for Investor Action

Unicycive's Legal Headache: What's Brewing? Here we go again, folks. If you're holding shares of Unicycive Therapeutics, Inc. (UNCY), buckle up because it's looking like a storm's on the horizon. The Law Offices of Howard G. Smith have dropped the news that shareholders can step up to lead a securities fraud class action lawsuit against the company. That chance to be part...

AMD CEO, Global Leaders Converge At IMPERIA Summit

A Clash of Giants in New York The trade floors are buzzing in New York as the world's economic heavyweights and tech titans gather for the inaugural IMPERIA Summit. You can almost smell the pressure and ambition wafting through the streets when folks like AMD's CEO, Lisa Su, share the stage with geopolitical power players like President Trump and China's President Xi...